Newron Pharmaceuticals S.p.A. | Mutual Funds
Mutual Funds that own Newron Pharmaceuticals S.p.A.
Polar Capital Funds Plc - Biotechnology Fund
250,000
1.4%
0
0.54%
07/31/2018
New Capital UCITS Fund Plc - Swiss Select Equity Fund
175,000
0.98%
0
0.97%
04/30/2018
Polar Capital Global Healthcare Growth & Income Trust Plc
148,525
0.83%
49,952
0.36%
09/30/2017
UniSector: BioPharma
120,000
0.67%
-29,140
0.37%
03/31/2018
CSIF Switzerland Total Market Index
104,459
0.59%
-1,414
0.01%
05/31/2018
UBS (CH) Equity Fund - Small Caps Switzerland
102,140
0.56%
0
0.32%
12/29/2017
UBS (CH) Equity Fund - Mid Caps Switzerland
91,302
0.51%
0
0.2%
12/29/2017
Stream Invest
81,000
0.45%
-2,000
2.59%
07/27/2018
Herculis Partners Aries Fund
80,912
0.45%
-23,169
15.6%
07/31/2018
RFP Swiss Equity Plus
69,217
0.39%
0
0.93%
08/31/2018
| Address |
via Ludovico Ariosto 21
Bresso Milan 20091
Italy
|
|
Employees
|
- |
| Website |
http://www.newron.com |
| Updated |
07/08/2019 |
| Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Its products include Xadago for Parkinson's disease; sarizotan for patients with Rett syndrome; and ralfinamide for patients with rare pain indications. The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy. |
